Giuseppe
Emeritus
(...)
(...)
http://www.emea.europa.eu/humandocs/PDFs/EPAR/tamiflu/Tamiflu-H-402-II-20.pdf
-------
According to
[FONT=TimesNewRoman,Italic][FONT=TimesNewRoman,Italic]Crain SM, et al. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance
in mice. Brain Res. 2004;995:260-266[/FONT][/FONT], inhibition of neuraminidase, the enzyme responsible for conversion of abundant polysialogangliosides to GM1 ganglioside, seemed to have dramatic effects on opioid analgesia and hyperalgesia in mice. Co-administration of oseltamivir with morphine markedly enhanced morphine-induced analgesia within the first hour of co-treatment. These results are intriguing from several points of view. The MAH stated that this is the only report of such findings, and it would be important to see replication of these data by other groups, and, in addition, in another species. The paper assessed only one behavioural parameter (tail flick latency) and there are other animal models that can be used for studying this interaction. In October 2005, the CHMP adopted a Request for Supplementary Information (RSI) addressed to the MAH and requested clarifications on this point.
in mice. Brain Res. 2004;995:260-266[/FONT][/FONT], inhibition of neuraminidase, the enzyme responsible for conversion of abundant polysialogangliosides to GM1 ganglioside, seemed to have dramatic effects on opioid analgesia and hyperalgesia in mice. Co-administration of oseltamivir with morphine markedly enhanced morphine-induced analgesia within the first hour of co-treatment. These results are intriguing from several points of view. The MAH stated that this is the only report of such findings, and it would be important to see replication of these data by other groups, and, in addition, in another species. The paper assessed only one behavioural parameter (tail flick latency) and there are other animal models that can be used for studying this interaction. In October 2005, the CHMP adopted a Request for Supplementary Information (RSI) addressed to the MAH and requested clarifications on this point.
(...)
http://www.emea.europa.eu/humandocs/PDFs/EPAR/tamiflu/Tamiflu-H-402-II-20.pdf
-------